The abnormal function of CD39+ regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia
- PMID: 31154474
- DOI: 10.1007/s00277-019-03716-9
The abnormal function of CD39+ regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia
Abstract
Primary immune thrombocytopenia is an autoimmune disease, characterized with decreased platelet and increased risk of bleeding. Recent studies have shown the reduction and dysfunction of regulatory T (Treg) cells in ITP patients. CD39 is highly expressed on the surface of Treg cells. It degrades ATP to AMP and CD73 dephosphorylates AMP into adenosine. Then adenosine binds with adenosine receptor and suppresses immune response by activating Treg cells and inhibiting the release of inflammatory cytokines from effector T (Teff) cells. Adenosine receptor has several subtypes and adenosine A2A receptor (A2AR) plays a crucial role especially within lymphocytes. The CD39+ Treg cells and the expression of A2AR showed abnormality in some autoimmune disease. But knowledge of CD39+ Treg cells and A2AR which are crucial in the adenosine immunosuppressive pathway is still limited in ITP. Thirty-one adult patients with newly diagnosed ITP were enrolled in this study. CD39 and A2AR expression was measured by flow cytometry and RT-PCR. The function of CD39 was reflected by the change of ATP concentration detected by CellTiter-Glo Luminescent Cell Viability Assay. CD39 expression within CD4+CD25+ Treg cells in ITP patients was decreased compared to normal controls. After high-dose dexamethasone therapy, response (R) group showed increased CD39 expression within Treg cells while non-response (NR) group did not show any difference in contrast to those before treatment. The expression of A2AR in CD4+CD25- Teff and CD4+CD25+ Treg cells was both lower in ITP patients than that of normal controls. After therapy, CD4+CD25- Teff cells had higher A2AR expression while CD4+CD25+ Treg cells did not show any difference in comparison to that before treatment. The enzymatic activity of CD39 was damaged in ITP patients and improved after high-dose dexamethasone therapy. In ITP, there was not only numerical decrease but also impaired enzymatic activity in CD39+ Treg cells. After high-dose dexamethasone treatment, these two defects could be reversed. Our results also suggested that ITP patients had reduced A2AR expression in both CD4+CD25+ Treg cells and CD4+CD25- Teff cells. CD4+CD25- Teff cells had increased A2AR expression after treatment.
Keywords: A2AR; Adenosine receptor; CD39; Dexamethasone; Immune thrombocytopenia; Regulatory T cell.
Similar articles
-
Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4+ CD25high Foxp3+ regulatory T-cells in psoriasis.Australas J Dermatol. 2018 Feb;59(1):e31-e38. doi: 10.1111/ajd.12561. Epub 2017 Mar 15. Australas J Dermatol. 2018. PMID: 28295154 Free PMC article.
-
Evaluation of the expression and function of the P2X7 receptor and ART1 in human regulatory T-cell subsets.Immunobiology. 2016 Jan;221(1):84-93. doi: 10.1016/j.imbio.2015.07.018. Epub 2015 Jul 29. Immunobiology. 2016. PMID: 26307000
-
Correction of abnormal T cell subsets by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.Immunol Lett. 2013 Jul-Aug;154(1-2):42-8. doi: 10.1016/j.imlet.2013.08.006. Epub 2013 Aug 28. Immunol Lett. 2013. PMID: 23994430
-
Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role?Transplant Rev (Orlando). 2010 Apr;24(2):52-66. doi: 10.1016/j.trre.2010.01.002. Epub 2010 Feb 11. Transplant Rev (Orlando). 2010. PMID: 20153159 Review.
-
CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia.Semin Hematol. 2013 Jan;50 Suppl 1:S43-9. doi: 10.1053/j.seminhematol.2013.03.018. Semin Hematol. 2013. PMID: 23664516 Review.
Cited by
-
Review immune response of targeting CD39 in cancer.Biomark Res. 2023 Jun 7;11(1):63. doi: 10.1186/s40364-023-00500-w. Biomark Res. 2023. PMID: 37287049 Free PMC article. Review.
-
Transcriptomic Analysis of Spleen Revealed Mechanism of Dexamethasone-Induced Immune Suppression in Chicks.Genes (Basel). 2020 May 6;11(5):513. doi: 10.3390/genes11050513. Genes (Basel). 2020. PMID: 32384708 Free PMC article.
-
Recombinant Thrombopoietin Effectively Shortens the Time to Response and Increases Platelet Counts in Elderly Patients with Severe Immune Thrombocytopenia.J Clin Med. 2022 Sep 29;11(19):5763. doi: 10.3390/jcm11195763. J Clin Med. 2022. PMID: 36233631 Free PMC article.
-
Proinflammatory plasticity towards Th17 paradigm of regulatory T cells consistent with elevated prevalence of TGFBR2 variants in elderly patients with primary immune thrombocytopenia.BMC Immunol. 2023 Apr 7;24(1):6. doi: 10.1186/s12865-023-00541-8. BMC Immunol. 2023. PMID: 37029342 Free PMC article.
-
Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia.J Clin Med. 2021 Jul 30;10(15):3403. doi: 10.3390/jcm10153403. J Clin Med. 2021. PMID: 34362187 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials